Every 10-Q that Personalis (PSNL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PSNL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PSNL filings page.
Personalis, Inc., a cancer genomics testing company, reported second‑quarter 2026 revenue of $22.357 million, up from $17.203 million a year earlier, driven mainly by pharma testing services and growing clinical diagnostic revenue. Six‑month 2026 revenue was $37.829 million, roughly flat versus 2025.
Losses remain substantial: net loss was $31.683 million for the quarter and $61.715 million for the first half, with higher research and development and selling, general and administrative expenses. Net cash used in operating activities was $48.248 million in the first half of 2026. As of June 30, 2026, Personalis held $93.968 million in cash and cash equivalents and $118.690 million in short‑term investments, with total assets of $312.135 million and stockholders’ equity of $235.161 million.
Revenue is concentrated, with Merck, the VA Million Veteran Program, and Moderna each contributing meaningful portions. Personalis also raised $25.503 million net through at‑the‑market stock sales in the first half. After quarter‑end, the company agreed to be acquired by Tempus AI, Inc. in a stock‑for‑stock merger, with each share of Personalis common stock to receive Tempus Class A shares based on an Exchange Ratio tied to Tempus’ volume‑weighted average price and a floor of 0.3356, and Tempus may elect to pay up to 50% of the consideration in cash at $16.25 per share, subject to proration and customary closing conditions.
Personalis, Inc. reported first-quarter 2026 revenue of $15.5 million, down 25% from $20.6 million a year earlier, as pharma testing, enterprise sales, and population sequencing all declined. Enterprise revenue dropped sharply as work with Natera wound down, while VA population sequencing revenue also fell.
Clinical diagnostic revenue rose to $1.4 million from $0.3 million, helped by new Medicare coverage decisions for NeXT Personal Dx in breast cancer and non-small cell lung cancer. Total costs and expenses increased to $47.6 million, leading to a net loss of $30.0 million, compared with a $15.8 million loss a year earlier.
Personalis ended March 31, 2026 with $233.2 million in cash, cash equivalents, and short-term investments and $0.9 million of debt. Operating activities used $22.5 million of cash in the quarter, and the company raised $21.0 million via at-the-market common stock sales.
Personalis, Inc. reported Q3 results and liquidity updates. Revenue was $14.5M for the quarter, down from $25.7M a year ago, reflecting lower enterprise and population sequencing activity. Pharma tests and services contributed $13.1M. The company posted a net loss of $21.7M versus a prior-year net loss of $39.1M, which previously included a large noncash warrant fair value charge.
Year‑to‑date revenue was $52.3M versus $67.8M last year, with operating cash use of $52.7M. Cash and cash equivalents were $50.0M and short‑term investments were $100.5M as of September 30, 2025. Shares outstanding were 88,804,348 as of October 28, 2025. During the nine months, the company raised $17.8M net via its ATM program.
Customer concentration remained significant, including contributions from Moderna, Regeneron and Pfizer in the period. The Tempus commercialization agreement continued, with $6.0M in market development fees received and amortizing against promotional costs.